Business, energy, technology, markets and global industry news from Business News Today

Incyte

PharmaDeviceNews Incyte
Representative image: Laboratory research into blood-clotting disorders highlights Star Therapeutics’ VGA039 programme as complete Phase 1/2 von Willebrand disease data head to ISTH 2026.
Pharma & Biotech

Why Star Therapeutics’ complete VGA039 dataset matters for the future of von Willebrand disease care

See why Star Therapeutics’ complete VGA039 data at ISTH 2026 could reshape von Willebrand disease prophylaxis and Incyte’s strategy.

Read More
Incyte’s Opzelura wins positive CHMP opinion for moderate atopic dermatitis in Europe
Pharma & Biotech

Incyte’s Opzelura wins positive CHMP opinion for moderate atopic dermatitis in Europe

The positive opinion moves ruxolitinib cream closer to a broader European label for adults inadequately controlled by standard topical therapies, opening a potential treatment position between conventional creams and systemic medicines.

Read More
Representative image of a clinician reviewing skeletal imaging, illustrating Mirum Pharmaceuticals and Incyte’s zilurgisertib Phase 2 progress in fibrodysplasia ossificans progressiva and the rare disease treatment questions facing regulators.
Pharma & Biotech

Why Mirum Pharmaceuticals and Incyte’s zilurgisertib data could reset expectations in FOP treatment

Read how Mirum and Incyte’s zilurgisertib Phase 2 data could reshape FOP treatment, FDA review risk and rare disease strategy.

Read More
Representative image: An oncologist reviews lymphoma scan data in a clinical setting as Incyte’s tafasitamab combination shows improved progression-free survival in high-risk diffuse large B-cell lymphoma, raising new questions about the future of first-line DLBCL treatment.
Pharma & Biotech

Incyte’s frontMIND data put pressure on decades-old R-CHOP dominance in high-risk DLBCL

Find out how Incyte’s tafasitamab data could reshape first-line treatment expectations in high-risk DLBCL.

Read More
Representative image: A hematology clinician reviews treatment data in a clinical lab setting as Incyte’s FDA approval of once-daily Jakafi XR highlights the next phase of ruxolitinib therapy for myelofibrosis, polycythemia vera and graft-versus-host disease.
Pharma & Biotech

Can Jakafi XR defend Incyte’s ruxolitinib franchise as dosing convenience becomes strategic?

Jakafi is mature, but dosing still matters. Incyte’s Jakafi XR approval could extend ruxolitinib’s strategic life in hematology.

Read More
Pharma & Biotech

Incyte brings Phase 3 tafasitamab data to ASCO 2026, but will frontMIND reshape first-line DLBCL treatment?

Incyte’s Phase 3 tafasitamab data are headed to ASCO 2026. Read what frontMIND could change for first-line DLBCL and what risks still remain.

Read More
Pharma & Biotech

Why Incyte’s povorcitinib 54-week results matter for hidradenitis suppurativa treatment

Incyte's povorcitinib reaches 71.4% HiSCR50 at 54 weeks in HS. Analysis of what the STOP-HS data mean for the JAK1 class and the treatment landscape.

Read More
Pharma & Biotech

Can Incyte’s 54-week povorcitinib data redefine the oral treatment landscape in hidradenitis suppurativa?

Incyte presents 54-week STOP-HS phase 3 data for povorcitinib at AAD 2026. Analyst review of durability, safety, and what the dataset means for the NDA.

Read More